Current Report Filing (8-k)
April 21 2017 - 5:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 20, 2017
XOMA CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
000-14710
|
|
Delaware
|
|
52-2154066
|
(Commission
File Number)
|
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
|
|
2910 Seventh Street, Berkeley, California
|
|
94710
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(510) 204-7200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02
|
Termination of a Material Definitive Agreement.
|
On April 20, 2017, XOMA Corporation (the
Company) received notice from Novo Nordisk A/S, Novo Allé, Bagsværd, Denmark (Novo Nordisk) of Novo Nordisks termination of its Exclusive License Agreement with the Company (the License Agreement) due
to strategic and business reasons. The termination of the License Agreement will be effective ninety (90) days from April 20, 2017 in accordance with Section 10.2 of the License Agreement.
Item 7.01
|
Regulation FD Disclosure.
|
Based on the termination of the License Agreement, the Company updates its
prior guidance regarding potential milestone payments payable under license agreements with various of the Companys partners over the next 36 months to decrease such guidance from $50 million to $40 million. Beginning on
April 21, 2017, the Company intends to make available to investors updated presentation slides regarding its revised guidance. These presentation slides will be available on the Companys website, www.xoma.com, under the Investor Relations
tab.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
XOMA CORPORATION
|
|
|
|
|
Date April 21, 2017
|
|
|
|
|
|
/s/ Thomas Burns
|
|
|
|
|
|
|
Thomas Burns
|
|
|
|
|
|
|
Senior Vice President, Finance and Chief Financial Officer
|
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024